GTDC1

Across TCGA pan-cancer cohorts, GTDC1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated GTDC1 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher GTDC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GTDC1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

GBM, ACC, and LUSC are the cancer types where GTDC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.069	0.415	<.001	18	view →
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
LUSC	OS	Median	III,IV	0.011	0.664	<.001	10	view →
READ	DFS	Median	All	0.274	0.701	.017	9	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →
COAD	DFS	Median	II,III,IV	0.166	0.497	.027	6	view →
SKCM	DFS	Median	II,III,IV	0.087	0.708	<.001	6	view →
UCEC	DFS	Median	All	0.925	0.627	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

GTDC1–GBM (OS)

Open the GBM breakdown →